Kevin Baxter, DO
Ophthalmology · Mishawaka, INNPI 1609161686
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (43.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Biotissue Holdings Inc. at 49.6% of the total. Reporting peaked in 2020 at $2,679 and has fallen 86.2% since, to $370 in 2025.
Across 86 payments — averaging $77.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotissue Holdings Inc.$3K
- AbbVie$1K
- Mallinckrodt Hospital Products Inc.$409
- Alcon$362
- Sight Sciences, Inc.$255
- Glaukos Corporation$194
- plus $1K from 12 others
What the payments were for
- Consulting fees$1,60024%
- Travel & lodging$1,30120%
- Food & beverage$2,89944%
- Education$85013%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotissue Holdings Inc. | 20 | $3,299 |
| AbbVie(2 entities) | 18 | $1,122 |
| Mallinckrodt Hospital Products Inc. | 5 | $409 |
| Alcon | 7 | $362 |
| Sight Sciences, Inc. | 10 | $255 |
| Glaukos Corporation | 2 | $194 |
| Vantage Technology LLC | 2 | $146 |
| Amgen | 2 | $143 |
| Sun Pharmaceutical Industries Inc. | 1 | $125 |
| Bausch & Lomb Americas Inc. | 1 | $125 |
| Rxsight Inc | 1 | $124 |
| Novartis | 7 | $98 |
| Coopervision Inc. | 2 | $97 |
| Kala Pharmaceuticals, Inc. | 3 | $58 |
| Ocular Therapeutix, Inc. | 2 | $27 |
| Rayner Intraocular Lenses Limited | 1 | $23 |
| Alimera Sciences, Inc. | 1 | $23 |
| Dompe US, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prokera$2,703
- AmnioGraft$2,703
- AmnioGuard$2,703
- ACTHAR$266
- iDoseTR$172
- iStent Infinite$172
- OMNI(R) SURGICAL SYSTEM (US)$146
- AcrySof IQ PanOptix$129
- CEQUA$125
- INFUSE$125
- TEPEZZA$125
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$124
- ORA$123
- DURYSTA$100
How this compares
$6,651 in reported general payments places this provider in the 85th percentile of 266 ophthalmology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 30 | $13,332 |
| CombiganBrimonidine Tartrate/Timolol | 11 | $4,645 |
| Alphagan PBrimonidine Tartrate | 15 | $3,875 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 20 | $3,858 |
| Prednisolone Acetate | 143 | $3,703 |
| Atropine Sulfate | 93 | $2,795 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 22 | $2,049 |
| Latanoprost | 243 | $1,724 |
| Travoprost | 21 | $1,688 |
| Loteprednol Etabonate | 12 | $1,450 |
| Dorzolamide Hcl | 70 | $920 |
| Timolol Maleate | 123 | $913 |
| Brimonidine Tartrate | 72 | $911 |
| ErythromycinErythromycin Base | 50 | $410 |
| Ketorolac Tromethamine | 14 | $403 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Alphagan P | $1,122 | $21,85356 claims |
| AlconSimbrinza | $362 | $3,85820 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 266 ophthalmology providers in Indiana.
Other ophthalmology in Mishawaka
- Vanessa NgakengMishawaka$4K
- Shamik BafnaLafayette$505K
- Kevin WaltzIndianapolis$199K
- Janet HummerIndianapolis$96K
- Francis PriceIndianapolis$67K
- Omar DukarEvansville$43K
- Gerald RoperBatesville$34K
- Dwight SilveraEvansville$28K
- Michael OrrIndianapolis$26K
- Matthew FengIndianapolis$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.